Shares of Exact Sciences Corp. (NASDAQ:EXAS) were down 1.5% during mid-day trading on Thursday . The company traded as low as $12.51 and last traded at $12.90, with a volume of 1,973,109 shares traded. The stock had previously closed at $13.10.

A number of analysts recently issued reports on EXAS shares. BTIG Research restated a “buy” rating on shares of Exact Sciences Corp. in a report on Tuesday, May 10th. Craig Hallum restated a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, June 22nd. Jefferies Group restated a “buy” rating and set a $13.00 price objective on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Robert W. Baird restated an “outperform” rating and set a $15.00 price objective (up previously from $12.00) on shares of Exact Sciences Corp. in a report on Wednesday, June 22nd. Finally, Zacks Investment Research upgraded shares of Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Tuesday, April 26th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Exact Sciences Corp. has an average rating of “Hold” and an average target price of $10.17.

The stock’s 50 day moving average is $9.89 and its 200 day moving average is $7.42. The company’s market capitalization is $1.25 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the prior year, the business earned ($0.40) earnings per share. The company earned $14.80 million during the quarter, compared to the consensus estimate of $15.17 million. The firm’s quarterly revenue was up 244.2% compared to the same quarter last year. Equities research analysts anticipate that Exact Sciences Corp. will post ($2.00) EPS for the current year.

A number of hedge funds recently modified their holdings of the company. Eagle Asset Management bought a new stake in shares of Exact Sciences Corp. during the third quarter worth about $39,880,000. OppenheimerFunds Inc. increased its stake in shares of Exact Sciences Corp. by 455.5% in the fourth quarter. OppenheimerFunds Inc. now owns 2,777,430 shares of the company’s stock worth $25,636,000 after buying an additional 2,277,430 shares in the last quarter. US Bancorp DE increased its stake in shares of Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock worth $2,119,000 after buying an additional 5,109 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock worth $1,640,000 after buying an additional 2,809 shares in the last quarter.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.